Morgan Stanley cut shares of Alphatec (NASDAQ:ATEC – Free Report) from an overweight rating to an equal weight rating in a research report sent to investors on Thursday morning, Marketbeat reports.
Other equities analysts have also recently issued research reports about the company. Canaccord Genuity Group restated a buy rating and issued a $25.00 price target on shares of Alphatec in a research report on Thursday, July 25th. Barclays started coverage on Alphatec in a research report on Monday, July 8th. They set an overweight rating and a $19.00 target price on the stock. Needham & Company LLC reiterated a buy rating and set a $23.00 target price on shares of Alphatec in a research report on Thursday. Piper Sandler dropped their target price on Alphatec from $17.00 to $12.00 and set an overweight rating on the stock in a research report on Thursday. Finally, Stifel Nicolaus dropped their target price on Alphatec from $19.00 to $16.00 and set a buy rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $19.11.
View Our Latest Report on ATEC
Alphatec Stock Performance
Alphatec (NASDAQ:ATEC – Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The company had revenue of $145.57 million during the quarter, compared to analyst estimates of $144.55 million. Alphatec had a negative net margin of 33.48% and a negative return on equity of 758.98%. The business’s revenue was up 24.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.43) EPS. Analysts predict that Alphatec will post -1.04 EPS for the current fiscal year.
Insider Activity at Alphatec
In related news, General Counsel Tyson Eliot Marshall sold 50,232 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total value of $546,524.16. Following the sale, the general counsel now owns 245,638 shares of the company’s stock, valued at approximately $2,672,541.44. The transaction was disclosed in a filing with the SEC, which is available through this link. 22.80% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Alphatec
Institutional investors and hedge funds have recently bought and sold shares of the stock. Cerity Partners LLC purchased a new stake in Alphatec in the 4th quarter valued at approximately $28,451,000. Charles Schwab Investment Management Inc. lifted its stake in Alphatec by 20.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 746,781 shares of the medical technology company’s stock valued at $11,284,000 after buying an additional 125,488 shares in the last quarter. Pura Vida Investments LLC purchased a new stake in Alphatec in the 4th quarter valued at approximately $4,609,000. First Light Asset Management LLC lifted its stake in Alphatec by 97.0% in the 4th quarter. First Light Asset Management LLC now owns 5,976,851 shares of the medical technology company’s stock valued at $90,310,000 after buying an additional 2,943,310 shares in the last quarter. Finally, Congress Asset Management Co. MA purchased a new stake in Alphatec in the 1st quarter valued at approximately $1,829,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.
About Alphatec
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Featured Stories
- Five stocks we like better than Alphatec
- Investing In Preferred Stock vs. Common Stock
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- What Are Dividend Champions? How to Invest in the Champions
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
- How to Buy Cheap Stocks Step by Step
- Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.